

FIG. 1




Figure 2.2A, 2.2B, 2.2C, 2.2D, and 2.2E are schematic diagrams of the structure of the various classes of immunoglobulin (Ig) molecules. The diagrams illustrate the arrangement of heavy (H) and light (L) chains, the variable (V) and constant (C) regions, and the disulfide bonds that link the chains together. The classes shown are IgG, IgD, IgE, IgA (dimer), and IgM (pentamer).

Fig.2A

IgG




Fig.2B

IgD







Fig.2C

IgE



IgA (dimer)

Fig.2D



IgM (pentamer)

Fig.2E

	230	240	250	260	270
humIgG1	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV				
humIgG2	PAP-PVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYV				
humIgG3	PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYV				
humIgG4	PAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSEQEDPEVQFNWYV				
murIgG1	---TVPEVSSVFIFPPKPKDVLTLTPKVTCTVVVDISKDDPEVQFSWFV				
murIgG2A	PAPNLLGGPSVFIFPPKIKDVLMSLSPIVTCVVVDVSEDDPDVQISWFV				
murIgG2B	PAPNLEGGPSVFIFPPNIKDVLMSLTPKVTCTVVVDVSEDDPDVQISWFV				
murIgG3	PPGNILGGPSVFIFPPKPKDALMSLTPKVTCTVVVDVSEDDPDVHVSWFV				
	280	290	300	310	320
humIgG1	DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG2	DGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLP				
humIgG3	DGVEVHNAKTKPREEQFNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALP				
humIgG4	DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP				
murIgG1	DDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDCLNGKEFKCRVNSAAF				
murIgG2A	NNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMGKEFKCKVNNKDL				
murIgG2B	NNVEVHTAQTQTHREDYNSTIRVVSALPIQHQDWMGKEFKCKVNNKDL				
murIgG3	DNKEVHTAWTQPREAQYNSTFRVVSALPIQHQDWMRGKEFKCKVNNKALP				
	330	340	350	360	370
humIgG1	APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP				
			D L		SDIAV
humIgG2	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP				
humIgG3	APIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYP				
humIgG4	SSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYP				
murIgG1	APIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFP				
murIgG2A	APIERTISKPKGSVRAPQVYVLPPEEEMTKKQVTLTCMVTDFMP				
murIgG2B	SPIERTISKPKGLVRAPQVYTLPPPAEQLSRKDVSLTCLVVGFN				
murIgG3	APIERTISKPKGRAQTPQVYTIPPPREQMSKKKVSLTCLVTNFF				
	380	390	400	410	420
humIgG1	EWESNGQPENNYKTTTPVLDSDGSEFFLYSKLTVDKSRWQQGNV				
humIgG2	EWESNGQPENNYKTTTPMLDSDGSEFFLYSKLTVDKSRWQQGNV				
humIgG3	EWESSGQPENNYNTTTPMLDSDGSEFFLYSKLTVDKSRWQQGNV				
humIgG4	EWZSNGQPENNYKTTTPVLDSDGSEFFLYSRLTVDKSRWQEGNV				
murIgG1	EWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNQKSNWEAGNTFT				
murIgG2A	EWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSY				
murIgG2B	EWTNSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTD				
murIgG3	EWERNGELEQDYKNTTPILDSDGTYFLYSKLTVDTDQSWLQGEI				
	430	440			
humIgG1	EALHNHYTQKSLSLSPGK				
humIgG2	EALHNHYTQKSLSLSPGK				
humIgG3	EALHNRFTQKSLSLSPGK				
humIgG4	EALHNHYTQKSLSLSPGK				
murIgG1	EGLHNHHTTEKSLSHSPGK				
murIgG2A	EGLHNHHTTKSFSRTPGK				
murIgG2B	EGLKNYYLKKTISRSPGK				
murIgG3	EALHNHHTQKNLSRSPGK				

Figure 3





Fig. 5



HERCEPTIN[®] is a registered trademark of Genentech, Inc. All other trademarks are the property of their respective owners.




Fig. 6A




Fig. 6B





Fig. 6C

Fig. 7






Fig.8A




Fig.8C




Fig.8B






Fig.8D








Fig. 10B





Fig. 10A

Fig. 11 A-F



Downloaded from www.sciencedirect.com by [university of california, san diego] on 04/11/14. For personal use only.

Fig. 11G





Fig. 11H

OctHER2 - 5hr



Fig. 11 I



bioRxiv preprint doi: <https://doi.org/10.1101/123456>; this version posted May 1, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Fig. 12A




Fig. 12B





Fig. 12E




Fig. 12C




Fig. 12D

Fig. 13A




Fig. 13C




Fig. 13B




Fig. 13D




Fig. 14




Fig. 15




Figure 16 shows the results of the experiment. The graph plots the percentage of control (Y-axis) against the concentration of the substance in ng/ml (X-axis, logarithmic scale). The data points represent the mean values for six different cell lines: 3H3 octopus, 16E2 octopus 3.0A, 16E2 octopus 2.1, 16E2 octopus 2.6, 16E2 octopus 3.0B, and 16E2 octopus 5.8. The error bars represent the standard deviation. The graph shows that the percentage of control decreases as the concentration of the substance increases, with the 3H3 octopus cell line showing the most significant reduction in control percentage at higher concentrations.

Fig. 16




Fig. 17A




Fig. 17B






Fig. 18 A




16E2 Octopus (anti-DR5) - 2 day




APO2L - 2 day

Fig. 18 B



Figure 18B shows the effect of 16E2 Octopus (anti-DR5) on the growth of various cancer cell lines. The graph displays the percentage growth of cells over time (0 to 2 days) for different cell lines and concentrations of the antibody. The y-axis represents Percentage Growth (0 to 100) and the x-axis represents Log₁₀ of Sample Concentration (Vol. Dil.) (0 to 2). The legend indicates the cell lines and their corresponding symbols and line styles: SF-268 (solid line, filled circle), SF-395 (dashed line, open circle), U371 (dotted line, filled square), SNB-19 (dashed line, open square), SF-539 (dotted line, filled triangle), and SNB-75 (dashed line, open triangle).





16E2 Octopus (anti-DR5) - 2 day



APO2L - 2 day

[illegible]

16E2 Octopus (anti-DR5) - 2 day



APO2L - 2 day







Fig. 19 A

Figure 19A shows the growth of various cell lines in the presence of 16E2 Octopus (anti-DR5) for 6 days. The y-axis represents Percentage Growth (0 to 100) and the x-axis represents Log₁₀ of Sample Concentration (Vol. Dil.).




16E2 Octopus (anti-DR5) - 6 day




APO2L - 6 day

Fig. 19 B




16E2 Octopus (anti-DR5) - 6 day




APO2L - 6 day

Fig. 19 C



16E2 Octopus (anti-DR5) - 6 day



APO2L - 6 day

Fig. 20 A

16E2 Octopus (anti-DR5) 2 day

Panel/Cell Line	Time Zero	Log10 Concentration					Percent Growth					GI50	TGI	LC50		
		Mean Optical Densities					Percent Growth									
		Ctrl	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0						
Leukemia	CCRF-CEM	0.081	0.557	0.526	0.491	0.457	0.299	0.125	94	86	79	46	9	2.74E+01	>1.00E+02	>1.00E+02
	HU-60(TB)	0.487	1.935	1.821	1.827	1.486	0.843	0.561	92	93	69	25	5	1.64E+01	>1.00E+02	>1.00E+02
	K-562	0.238	1.548	1.548	1.525	1.473	1.494	1.458	100	98	94	96	93	>1.00E+02	>1.00E+02	>1.00E+02
	MOLT-4	0.215	1.046	0.976	0.908	0.890	0.888	0.874	92	83	81	81	79	>1.00E+02	>1.00E+02	>1.00E+02
	RPMI-8226	0.335	1.302	1.067	1.009	0.947	0.937	0.959	76	70	63	62	65	>1.00E+02	>1.00E+02	>1.00E+02
	SR	0.279	1.868	0.965	0.807	0.681	0.600	0.537	43	33	25	20	16	<1.00E+00	>1.00E+02	>1.00E+02
	Non-Small Cell Lung Cancer															
A549/ATCC	0.212	1.132	1.155	1.091	1.061	1.094	1.096	102	95	92	96	96	>1.00E+02	>1.00E+02	>1.00E+02	
EXVX	0.561	1.247	1.256	1.237	1.142	1.181	1.181	87	89	86	74	79	>1.00E+02	>1.00E+02	>1.00E+02	
HOP-62	0.363	1.082	1.147	1.156	1.191	1.182	1.158	109	110	115	114	111	<1.00E+02	>1.00E+02	>1.00E+02	
HOP-92	0.630	0.958	0.717	0.617	0.541	0.551	0.564	26	-2	-14	-13	-10	<1.00E+00	2.92E+00	>1.00E+02	
NCI-H226	0.269	0.702	0.660	0.588	0.531	0.541	0.539	90	74	61	63	62	>1.00E+02	>1.00E+02	>1.00E+02	
NCI-H23	0.602	1.657	1.581	1.525	1.463	1.512	1.540	93	88	82	86	89	>1.00E+02	>1.00E+02	>1.00E+02	
NCI-H322H	0.488	1.265	1.222	1.265	1.256	1.276	1.211	94	100	99	101	93	>1.00E+02	>1.00E+02	>1.00E+02	
NCI-H460	0.362	1.677	0.416	0.305	0.244	0.256	0.237	4	-16	-33	-29	-35	<1.00E+00	1.27E+00	>1.00E+02	
NCI-H522	0.374	0.954	0.868	0.830	0.804	0.838	0.839	85	79	74	78	80	>1.00E+02	>1.00E+02	>1.00E+02	
Colon Cancer																
COLO 205	0.145	0.829	0.003	-0.002	-0.008	0.004	0.009	-98	-100	-100	-98	-94	<1.00E+00	<1.00E+00	<1.00E+00	
HCC-2998	0.334	0.797	0.511	0.353	0.246	0.250	0.252	38	4	-26	-25	-25	<1.00E+00	3.70E+00	>1.00E+02	
HCT-116	0.385	2.058	1.341	1.051	1.008	0.926	0.904	57	40	37	32	31	<1.61E+00	>1.00E+02	>1.00E+02	
HCT-15	0.205	1.218	0.324	0.204	0.146	0.154	0.169	12	0	-29	-25	-18	<1.00E+00	3.03E+00	>1.00E+02	
HT29	0.322	1.464	1.547	1.523	1.566	1.553	1.485	107	105	109	108	102	>1.00E+02	>1.00E+02	>1.00E+02	
KM12	0.240	1.281	1.243	1.218	1.224	1.096	1.097	96	94	95	82	82	>1.00E+02	>1.00E+02	>1.00E+02	
SW-620	0.134	0.961	0.713	0.721	0.678	0.645	0.594	70	71	66	62	56	>1.00E+02	>1.00E+02	>1.00E+02	
CNS Cancer																
SF-268	0.360	1.045	1.005	1.008	0.992	1.013	0.970	94	94	92	95	89	>1.00E+02	>1.00E+02	>1.00E+02	
SF-295	0.512	1.311	0.344	0.313	0.312	0.313	0.282	-33	-39	-39	-39	-45	<1.00E+00	<1.00E+02	>1.00E+02	
SF-539	0.220	1.153	0.860	0.750	0.673	0.674	0.657	69	57	49	49	47	8.14E+00	>1.00E+02	>1.00E+02	
SNB-19	0.316	1.123	1.139	1.143	1.121	1.136	1.157	102	102	100	102	104	>1.00E+02	>1.00E+02	>1.00E+02	
SNB-75	0.326	0.637	0.651	0.640	0.596	0.623	0.628	104	101	87	96	97	>1.00E+02	>1.00E+02	>1.00E+02	
U251	0.197	0.981	0.766	0.718	0.642	0.620	0.636	73	66	57	54	56	>1.00E+02	>1.00E+02	>1.00E+02	
Melanoma																
LOX IMVI	0.349	1.703	1.589	1.510	1.366	1.321	1.299	92	86	75	72	70	>1.00E+02	>1.00E+02	>1.00E+02	
HALME-3H	0.350	0.732	0.643	0.600	0.555	0.557	0.553	77	65	53	54	53	>1.00E+02	>1.00E+02	>1.00E+02	
M14	0.320	1.246	0.982	0.783	0.716	0.689	0.703	72	50	43	40	41	3.16E+00	>1.00E+02	>1.00E+02	
SK-MEL-2	0.592	0.982	0.758	0.712	0.639	0.618	0.622	43	31	12	7	8	<1.00E+00	>1.00E+02	>1.00E+02	
SK-MEL-28	0.345	1.033	0.853	0.835	0.768	0.729	0.668	74	71	61	56	47	6.76E+01	>1.00E+02	>1.00E+02	
SK-MEL-5	0.346	2.111	1.937	1.893	1.770	1.869	1.721	90	88	81	86	78	>1.00E+02	>1.00E+02	>1.00E+02	
UACC-257	0.612	1.307	1.211	1.133	1.062	1.053	0.976	86	75	65	63	52	>1.00E+02	>1.00E+02	>1.00E+02	
UACC-62	0.597	1.806	1.509	1.318	1.166	1.038	1.024	75	60	47	36	35	7.66E+00	>1.00E+02	>1.00E+02	
Ovarian Cancer																
IGROV1	0.209	0.934	0.927	0.876	0.915	0.905	0.893	99	92	97	96	94	>1.00E+02	>1.00E+02	>1.00E+02	
OVCA-3	0.434	1.295	0.566	0.526	0.460	0.439	0.431	15	11	3	1	-1	<1.00E+00	5.19E+01	>1.00E+02	
OVCA-4	0.359	1.495	1.464	1.453	1.442	1.404	1.361	97	96	95	92	88	>1.00E+02	>1.00E+02	>1.00E+02	
OVCA-5	1.107	1.829	1.539	1.355	1.318	1.181	1.253	60	34	29	10	20	1.56E+00	>1.00E+02	>1.00E+02	
OVCA-8	0.238	0.890	0.903	0.875	0.881	0.923	0.882	102	98	99	105	99	>1.00E+02	>1.00E+02	>1.00E+02	
SK-OV-3	0.450	1.051	1.051	1.061	1.034	1.068	1.075	100	102	97	103	104	>1.00E+02	>1.00E+02	>1.00E+02	
Renal Cancer																
786-0	0.453	1.495	1.504	1.506	1.492	1.491	1.512	101	101	100	100	102	>1.00E+02	>1.00E+02	>1.00E+02	
A498	0.757	1.482	1.150	0.968	0.743	0.690	0.726	54	29	-2	-9	-4	1.21E+00	9.33E+00	>1.00E+02	
ACHN	0.360	1.644	1.336	1.290	0.931	0.904	0.899	76	72	44	42	42	7.98E+00	>1.00E+02	>1.00E+02	
CAXI-1	0.292	1.410	1.326	1.223	1.151	1.071	1.062	92	82	77	70	69	>1.00E+02	>1.00E+02	>1.00E+02	
RXP 393	0.546	1.151	1.107	1.203	1.149	1.156	1.157	93	109	100	101	101	>1.00E+02	>1.00E+02	>1.00E+02	
SN12C	0.511	1.145	0.962	0.839	0.755	0.730	0.788	71	52	39	34	44	3.70E+00	>1.00E+02	>1.00E+02	
TK-10	0.539	1.127	1.116	1.095	1.021	1.028	0.999	98	95	82	83	78	>1.00E+02	>1.00E+02	>1.00E+02	
DO-31	0.580	1.330	1.391	1.351	1.319	1.301	1.294	108	103	99	96	95	>1.00E+02	>1.00E+02	>1.00E+02	
Prostate Cancer																
PC-3	0.332	0.865	0.653	0.628	0.546	0.545	0.552	60	55	40	40	41	4.75E+00	>1.00E+02	>1.00E+02	
DU-145	0.336	1.268	1.174	1.189	1.130	1.135	1.112	90	91	85	85	83	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer																
MDA-MB-231/ATCC	0.361	1.913	1.881	1.935	1.827	1.950	2.020	98	101	94	102	107	>1.00E+02	>1.00E+02	>1.00E+02	
NCI/ADR-RES	0.331	0.988	0.958	0.976	0.977	0.992	0.996	95	98	98	101	101	>1.00E+02	>1.00E+02	>1.00E+02	
MDA-MB-435	0.579	1.268	1.146	1.048	0.976	0.977	1.018	82	65	58	58	64	>1.00E+02	>1.00E+02	>1.00E+02	
MDA-N	0.261	1.249	1.055	0.972	0.858	0.843	0.783	80	72	60	59	53	>1.00E+02	>1.00E+02	>1.00E+02	
BT-549	0.217	0.971	0.910	0.895	0.782	0.795	0.766	92	90	75	77	73	>1.00E+02	>1.00E+02	>1.00E+02	
T-47D	0.570	1.446	1.237	0.989	0.820	0.773	0.728	76	48	29	23	18	2.90E+00	>1.00E+02	>1.00E+02	
SK-BR-3	0.382	1.004	0.963	0.993	1.010	1.013	1.026	93	98	101	101	103	>1.00E+02	>1.00E+02	>1.00E+02	

Fig. 20 B

AP02L - 2 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities					Log10 Concentration					Percent Growth	G150	TGI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0						
Leukemia	CCRFP-CEM	0.081	0.576	0.400	0.510	0.443	0.447	0.476	64	87	73	74	80	>1.00E+02	>1.00E+02	>1.00E+02
	NU-60 (TB)	0.487	1.926	1.660	1.118	1.074	0.881	0.857	82	44	41	27	26	>1.00E+02	>1.00E+02	>1.00E+02
	K-562	0.238	1.596	1.629	1.557	1.416	1.371	1.349	102	97	87	83	82	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-4	0.215	1.126	1.132	1.131	1.136	1.136	1.167	101	101	101	101	104	>1.00E+02	>1.00E+02	>1.00E+02
	RPMI-8226	0.335	1.284	0.599	0.437	0.348	0.359	0.345	28	10	1	2	1	<1.00E+00	>1.00E+02	>1.00E+02
	SR	0.279	1.820	1.578	1.475	1.417	1.428	1.460	84	78	74	75	77	>1.00E+02	>1.00E+02	>1.00E+02
Non-Small Cell Lung Cancer	A549/ATCC	0.212	1.164	1.177	1.173	1.086	1.052	1.068	101	101	92	88	90	>1.00E+02	>1.00E+02	>1.00E+02
	ERYX	0.561	1.328	1.325	1.337	1.228	1.275	1.266	100	101	87	93	92	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-62	0.363	1.260	1.241	1.174	1.106	1.202	1.136	98	90	83	94	86	>1.00E+02	>1.00E+02	>1.00E+02
	HOP-92	0.630	1.002	0.843	0.788	0.755	0.753	0.766	57	43	33	33	37	>1.00E+02	>1.00E+02	>1.00E+02
	NCI-H226	0.269	0.642	0.651	0.691	0.677	0.665	0.663	102	113	109	106	106	>1.00E+02	>1.00E+02	>1.00E+02
	NCI-H23	0.602	1.620	1.597	1.636	1.626	1.641	1.670	98	102	101	102	105	>1.00E+02	>1.00E+02	>1.00E+02
Colon Cancer	NCI-H322H	0.488	1.265	1.138	1.054	0.821	0.808	0.779	84	73	43	41	37	>1.00E+02	>1.00E+02	>1.00E+02
	NCI-H460	0.362	1.562	0.342	0.228	0.171	0.140	0.124	-6	-37	-53	-61	-66	<1.00E+00	>1.00E+02	>1.00E+02
	NCI-H522	0.374	0.760	0.722	0.705	0.691	0.674	0.657	90	86	82	78	73	>1.00E+02	>1.00E+02	>1.00E+02
	COLO 205	0.145	0.814	0.029	0.025	0.015	0.021	0.021	-80	-83	-90	-86	-86	<1.00E+00	<1.00E+00	<1.00E+00
	HCC-2998	0.334	0.742	0.538	0.354	0.291	0.260	0.235	50	5	-13	-22	-30	<1.00E+00	>1.00E+02	>1.00E+02
	HCT-116	0.385	1.855	0.726	0.483	0.389	0.348	0.349	23	7	0	-10	-9	<1.00E+00	>1.00E+02	>1.00E+02
CNS Cancer	HCT-115	0.205	1.183	0.279	0.211	0.144	0.128	0.125	8	1	-30	-38	-39	<1.00E+00	>1.00E+02	>1.00E+02
	H29	0.322	1.477	1.515	1.485	1.404	1.462	1.446	103	101	94	99	97	>1.00E+02	>1.00E+02	>1.00E+02
	KM12	0.240	1.440	1.235	1.190	0.922	0.865	0.799	83	79	57	52	47	>1.00E+02	>1.00E+02	>1.00E+02
	SW-620	0.134	0.962	0.849	0.744	0.674	0.632	0.607	86	74	65	60	57	>1.00E+02	>1.00E+02	>1.00E+02
	CNS Cancer	0.360	0.874	0.891	0.873	0.886	0.901	0.898	103	100	102	105	105	>1.00E+02	>1.00E+02	>1.00E+02
	SF-268	0.512	1.273	0.862	0.728	0.636	0.670	0.603	46	28	16	21	12	>1.00E+02	>1.00E+02	>1.00E+02
Melanoma	SK-MEL-28	0.320	1.040	1.006	0.820	0.632	0.574	0.574	96	73	50	38	43	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-5	0.316	1.144	1.172	1.151	1.151	1.191	1.191	102	103	101	106	106	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-75	0.326	0.663	0.623	0.637	0.618	0.634	0.589	88	92	87	91	87	>1.00E+02	>1.00E+02	>1.00E+02
	U251	0.197	0.980	0.913	0.909	0.814	0.833	0.876	91	91	79	81	78	>1.00E+02	>1.00E+02	>1.00E+02
	Melanoma	0.349	1.657	1.606	1.494	1.415	1.380	1.464	96	88	81	79	85	>1.00E+02	>1.00E+02	>1.00E+02
	LOX IMVI	0.350	1.650	0.710	0.701	0.663	0.671	0.647	106	103	92	94	87	>1.00E+02	>1.00E+02	>1.00E+02
Ovarian Cancer	MALME-3H	0.320	1.267	1.213	1.130	1.167	1.124	1.104	94	85	89	85	83	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-2	0.592	1.003	0.879	0.929	0.920	0.905	0.954	70	82	80	76	88	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-28	0.345	1.061	1.051	1.028	0.986	0.991	0.930	99	95	89	90	82	>1.00E+02	>1.00E+02	>1.00E+02
	SK-MEL-5	0.346	2.127	2.076	2.082	2.081	2.217	2.042	97	98	97	105	95	>1.00E+02	>1.00E+02	>1.00E+02
	UACC-257	0.612	1.245	1.289	1.256	1.199	1.189	1.113	107	102	93	91	79	>1.00E+02	>1.00E+02	>1.00E+02
	UACC-62	0.597	2.056	1.844	1.677	1.650	1.675	1.582	85	74	72	74	68	>1.00E+02	>1.00E+02	>1.00E+02
Renal Cancer	IGROV1	0.209	0.916	0.947	0.982	0.912	0.960	0.973	104	109	99	106	108	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-3	0.434	1.456	0.983	0.787	0.765	0.658	0.651	54	34	32	22	21	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-4	0.359	1.518	1.472	1.477	1.274	1.310	1.180	96	96	79	82	71	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-5	1.107	1.815	1.700	1.618	1.446	1.452	1.493	84	72	48	49	54	>1.00E+02	>1.00E+02	>1.00E+02
	OVCAR-8	0.238	0.927	0.928	0.938	0.896	0.930	0.950	100	102	95	100	103	>1.00E+02	>1.00E+02	>1.00E+02
	SK-OV-3	0.450	1.167	1.126	1.123	1.077	1.162	1.175	94	94	87	99	101	>1.00E+02	>1.00E+02	>1.00E+02
Prostate Cancer	786-0	0.453	1.424	1.386	1.400	1.434	1.446	1.489	96	98	101	102	107	>1.00E+02	>1.00E+02	>1.00E+02
	A498	0.757	1.493	1.293	0.950	0.768	0.606	0.616	73	26	1	-20	-19	>1.00E+02	>1.00E+02	>1.00E+02
	ACHN	0.360	1.548	1.526	1.590	1.327	1.363	1.318	98	104	81	84	81	>1.00E+02	>1.00E+02	>1.00E+02
	CAX1-1	0.292	1.503	1.439	1.477	1.266	1.371	1.210	95	98	80	89	76	>1.00E+02	>1.00E+02	>1.00E+02
	KRF 393	0.546	1.208	1.172	1.170	1.087	1.086	1.058	95	94	82	82	77	>1.00E+02	>1.00E+02	>1.00E+02
	SK12C	0.511	1.155	1.055	1.072	1.050	1.080	1.064	85	87	84	88	86	>1.00E+02	>1.00E+02	>1.00E+02
Breast Cancer	TK-10	0.539	1.080	1.060	0.975	0.939	0.839	0.756	96	81	74	56	40	>1.00E+02	>1.00E+02	>1.00E+02
	DU-31	0.580	1.342	1.334	1.361	1.391	1.387	1.439	99	102	106	106	113	>1.00E+02	>1.00E+02	>1.00E+02
	PC-3	0.332	0.886	0.758	0.746	0.700	0.684	0.692	77	75	66	64	65	>1.00E+02	>1.00E+02	>1.00E+02
	DU-145	0.336	1.314	1.249	1.215	1.052	0.842	0.766	93	90	73	52	44	>1.00E+02	>1.00E+02	>1.00E+02
	Breast Cancer	0.361	2.217	1.918	1.618	1.333	1.279	1.180	84	68	52	49	44	>1.00E+02	>1.00E+02	>1.00E+02
	MCF7	0.331	0.947	0.987	1.016	0.975	0.985	0.981	106	111	104	106	105	>1.00E+02	>1.00E+02	>1.00E+02
T-47D	NCI/ADR-RES	0.590	0.986	0.985	0.988	0.958	0.924	1.020	100	100	93	84	109	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-MB-231/ATCC	0.579	1.049	1.074	1.055	1.045	1.047	1.077	105	101	99	100	106	>1.00E+02	>1.00E+02	>1.00E+02
	HS 578T	0.579	1.049	1.074	1.055	1.045	1.047	1.077	105	101	99	100	106	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-MB-435	0.261	1.392	1.329	1.274	1.027	1.055	0.954	91	90	68	70	61	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-N	0.217	0.929	0.859	0.897	0.806	0.807	0.807	90	96	83	83	83	>1.00E+02	>1.00E+02	>1.00E+02
	MDA-N	0.217	0.929	0.859	0.897	0.806	0.807	0.807	90	96	83	83	83	>1.00E+02	>1.00E+02	>1.00E+02
T-47D	MDA-N	0.570	1.415	1.383	1.377	1.394	1.297	1.256	96	96	86	86	81	>1.00E+02	>1.00E+02	>1.00E+02
	T-47D	0.382	1.044	1.014	1.025	1.000	1.054	0.955	95	97	93	101	87	>1.00E+02	>1.00E+02	>1.00E+02

Fig. 21 A

16E2 Octopus (anti-DR5) - 6 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				GI50	TGI	LC50			
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0						
Leukemia	CCRF-CEM	0.004	0.731	0.832	0.730	0.789	0.720	0.103	114	100	108	98	14	100	108	98	14	6.11E+01	>1.00E+02	>1.00E+02
	HL-60 (TB)	0.068	2.840	2.912	2.950	2.924	2.813	2.039	103	104	103	99	71	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	K-562	0.046	2.941	2.718	2.776	2.799	2.688	99	92	94	95	91	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02		
	MOLT-4	0.009	0.981	0.450	0.287	0.266	0.282	0.196	45	29	26	28	19	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	RPMI-8226	0.061	1.637	0.904	0.725	0.604	0.584	0.618	53	42	34	33	35	1.43E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SR	0.031	2.631	0.642	0.261	0.136	0.091	0.110	24	9	4	2	3	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Non-Small Cell Lung Cancer	A549/ATCC	0.021	2.721	2.734	2.443	2.524	2.458	2.314	100	90	93	90	85	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	EPHX	0.057	1.201	0.939	0.896	0.773	0.683	0.581	77	73	63	55	46	5.80E+01	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-62	0.059	0.922	0.750	0.767	0.683	0.595	0.541	80	82	72	62	56	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-92	0.110	0.792	0.642	0.573	0.577	0.525	0.512	78	68	68	61	59	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H23	0.103	1.191	1.103	1.027	1.069	1.034	1.057	92	85	89	86	88	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H322M	0.038	1.051	0.841	0.716	0.858	0.965	0.826	79	67	81	92	78	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Colon Cancer	NCI-H460	0.050	2.780	1.042	0.668	0.399	0.459	0.387	36	23	13	15	12	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H522	0.064	0.648	0.481	0.406	0.386	0.409	0.307	71	59	55	59	42	5.77E+01	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	COLO 205	0.001	1.430	-0.014	-0.033	-0.014	-0.014	-0.013	-100	-100	-100	-100	-100	<1.00E+00	<1.00E+00	<1.00E+00	<1.00E+00	<1.00E+00	<1.00E+00	
	HCC-2998	0.031	0.974	0.296	0.096	0.067	0.047	0.036	28	7	4	2	1	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	HCT-116	0.068	2.951	2.404	2.329	2.028	1.901	1.691	81	78	68	64	56	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	HCT-15	0.020	2.056	0.435	0.168	0.100	0.096	0.107	20	7	4	4	4	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
CNS Cancer	H729	0.052	2.528	2.445	2.325	2.293	2.387	2.210	97	92	91	94	87	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	KM12	0.010	0.708	0.390	0.334	0.486	0.290	0.283	54	46	68	40	39	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SW-620	0.010	2.141	1.392	1.302	1.282	1.145	0.966	65	61	60	53	45	4.95E+01	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SP-268	0.041	1.069	1.017	0.969	0.993	0.980	0.958	95	90	93	91	89	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SP-295	0.054	1.614	0.031	0.019	0.018	0.023	0.023	-43	-66	-67	-57	-57	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SP-539	0.030	1.468	0.875	0.672	0.624	0.646	0.572	59	45	41	43	38	2.05E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Melanoma	SK-MEL-2	0.045	1.813	1.594	1.598	1.544	1.794	1.822	88	88	85	99	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-28	0.095	1.316	0.703	0.668	0.603	0.524	0.478	52	49	44	38	34	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-5	0.045	1.885	1.902	1.947	1.880	1.916	1.895	101	103	100	102	101	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-257	0.070	0.841	0.504	0.447	0.420	0.393	0.376	56	49	45	42	40	2.64E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-62	0.121	1.601	1.119	0.932	0.781	0.764	0.810	67	55	45	43	47	5.44E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	IGROV1	0.018	1.567	1.476	1.603	1.622	1.529	1.510	94	102	104	98	96	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Ovarian Cancer	OVCA9-3	0.086	1.285	0.039	0.041	0.039	0.040	0.033	-55	-52	-55	-53	-62	<1.00E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-4	0.071	1.563	1.304	1.287	1.028	0.998	0.854	83	81	64	62	52	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-5	0.101	1.606	1.390	1.053	1.046	0.873	0.837	86	63	63	51	49	5.85E+01	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA9-8	0.020	1.565	1.634	1.571	1.587	1.630	1.570	104	100	101	104	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-OV-3	0.056	0.811	0.817	0.812	0.813	0.759	0.769	101	100	100	93	94	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	786-O	0.073	1.715	1.716	1.715	1.726	1.731	1.686	100	100	101	101	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Renal Cancer	A498	0.087	1.058	0.996	0.877	0.737	0.692	0.716	94	81	67	62	65	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	ACHN	0.041	1.970	1.331	1.307	0.016	0.020	0.020	67	14	-61	-51	-51	5.46E+00	3.92E+00	8.46E+00	>1.00E+02	>1.00E+02	>1.00E+02	
	CAXI-1	0.033	1.215	0.797	0.758	0.492	0.535	0.512	65	61	39	42	41	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	RXP 193	0.101	0.973	0.496	0.086	0.043	0.029	0.028	45	-15	-58	-71	-72	<1.00E+00	2.37E+00	8.08E+00	>1.00E+02	>1.00E+02	>1.00E+02	
	SN12C	0.054	1.263	0.669	0.504	0.358	0.315	0.249	51	37	25	22	16	1.08E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	TK-10	0.057	1.064	1.000	0.925	0.811	0.666	0.568	94	86	75	60	51	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Prostate Cancer	DU-311	0.095	1.457	1.201	0.838	0.701	0.476	0.418	81	55	44	28	24	5.32E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	PC-3	0.030	0.879	0.520	0.379	0.334	0.315	0.333	58	41	36	34	36	1.70E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	DG-145	0.057	1.962	1.887	1.790	1.717	1.662	1.654	96	91	87	84	84	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	MCF7	0.060	2.908	2.856	2.870	2.865	2.833	2.843	98	99	98	97	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI/ADR-RES	0.045	1.087	1.064	1.054	1.157	1.130	1.088	98	97	107	104	100	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	KDA-MB-231/ATCC	0.042	0.819	0.674	0.577	0.538	0.488	0.575	81	69	64	57	69	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	HS 578T	0.055	0.759	0.470	0.322	0.261	0.260	0.201	59	38	29	29	21	1.64E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	KDA-MB-435	0.041	2.284	1.227	0.955	0.806	0.819	0.723	53	41	34	35	30	3.03E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
Other	KDA-N	0.010	0.861	0.490	0.457	0.355	0.322	0.313	56	53	40	37	36	4.40E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	BT-549	0.049	1.316	0.995	0.521	0.364	0.319	0.261	74	35	22	18	12	2.01E+00	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	BT-20	0.049	0.656	0.613	0.564	0.528	0.526	0.505	98	89	83	98	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	
	BT-20	0.049	0.656	0.613	0.564	0.528	0.526	0.505	98	89	83	98	98	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	>1.00E+02	


Fig. 21 B

Figure 21B shows the results of the APO2L - 6 day assay. The data is presented in a table format, showing the results of the assay for various cell lines and time points.






APO2L - 6 day

Panel/Cell Line	Time Zero	Ctrl	Mean Optical Densities				Log10 Concentration				Percent Growth				GI50	TOI	LC50
			0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0	0.5	1.0	1.5	2.0			
Leukemia	CCRF-CEM	0.004	0.842	0.753	0.453	0.365	0.574	0.569	89	54	43	68	67	<1.00E+00	>1.00E+02	>1.00E+02	
	HL-60(TB)	0.068	2.822	0.712	0.317	0.202	0.116	0.080	23	9	5	2	0	<1.00E+00	>1.00E+02	>1.00E+02	
	K-562	0.046	2.792	2.962	3.017	2.920	2.716	2.626	106	108	105	97	94	>1.00E+02	>1.00E+02	>1.00E+02	
	MOLT-4	0.009	1.040	0.929	0.928	0.965	0.999	0.797	89	89	93	96	76	>1.00E+02	>1.00E+02	>1.00E+02	
	RFH1-8226	0.061	1.661	0.072	0.038	0.041	0.025	0.022	1	-39	-34	-59	-65	<1.00E+00	1.02E+00	2.10E+01	
	SR	0.031	2.591	2.540	2.234	1.915	1.822	1.708	98	86	74	70	65	>1.00E+02	>1.00E+02	>1.00E+02	
	Non-Small Cell Lung Cancer	0.021	2.037	2.071	2.070	2.029	2.045	2.038	102	100	100	100	100	>1.00E+02	>1.00E+02	>1.00E+02	
Colon Cancer	AS49/ATCC	0.021	2.037	2.071	2.070	2.029	2.045	2.038	102	100	100	100	100	>1.00E+02	>1.00E+02	>1.00E+02	
	EXVX	0.057	1.052	1.070	1.039	1.078	1.000	0.962	102	98	103	95	91	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-62	0.059	0.891	0.854	0.854	0.787	0.725	0.662	96	95	87	80	72	>1.00E+02	>1.00E+02	>1.00E+02	
	HOP-92	0.110	0.906	0.750	0.698	0.700	0.705	0.723	80	74	74	75	77	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H23	0.103	1.184	1.180	1.147	1.122	1.185	1.163	100	97	94	100	98	>1.00E+02	>1.00E+02	>1.00E+02	
	NCI-H322M	0.038	0.976	0.824	0.606	0.488	0.436	0.346	84	60	48	42	33	8.30E+00	>1.00E+02	>1.00E+02	
	NCI-H460	0.050	2.857	0.536	0.239	0.153	0.063	0.048	17	7	4	0	-4	<1.00E+00	3.57E+01	>1.00E+02	
Colorectal Cancer	NCI-H522	0.064	0.461	0.354	0.344	0.336	0.263	0.238	73	70	68	50	44	3.22E+01	>1.00E+02	>1.00E+02	
	COLO 205	0.001	1.396	-0.005	-0.007	0.006	0.002	0.014	-100	-100	0	0	1	<1.00E+00	>1.00E+02	>1.00E+02	
	HCC-2998	0.031	1.083	0.682	0.274	0.305	0.202	0.189	62	23	26	16	15	1.43E+00	>1.00E+02	>1.00E+02	
	HCT-116	0.068	3.014	2.272	1.606	1.249	0.953	0.821	75	52	40	30	26	3.91E+00	>1.00E+02	>1.00E+02	
	HCT-15	0.020	2.169	0.196	0.054	0.039	0.018	0.030	8	2	1	-10	0	<1.00E+00	>1.00E+02	>1.00E+02	
	HCT29	0.052	1.968	1.970	1.962	2.035	2.034	2.063	100	100	103	103	105	>1.00E+02	>1.00E+02	>1.00E+02	
	Hx12	0.010	0.633	0.249	0.218	0.133	0.052	0.052	38	33	20	7	7	>1.00E+00	>1.00E+02	>1.00E+02	
CNS Cancer	SK-M20	0.010	2.236	1.477	1.220	1.040	0.943	0.608	66	54	46	42	27	5.89E+00	>1.00E+02	>1.00E+02	
	SK-N-SH	0.041	0.893	0.891	0.914	0.906	0.852	0.927	100	103	102	95	104	>1.00E+02	>1.00E+02	>1.00E+02	
	SF-268	0.054	1.659	1.054	0.706	0.634	0.557	0.529	62	41	36	31	30	1.92E+00	>1.00E+02	>1.00E+02	
	SF-295	0.030	1.513	1.411	1.046	1.113	1.034	0.689	93	68	73	68	44	7.59E+01	>1.00E+02	>1.00E+02	
	SF-539	0.016	1.579	1.639	1.558	1.586	1.650	1.563	104	99	100	105	99	>1.00E+02	>1.00E+02	>1.00E+02	
	SNB-19	0.063	0.524	0.484	0.529	0.497	0.531	0.531	91	101	94	102	102	>1.00E+02	>1.00E+02	>1.00E+02	
	SNB-75	0.012	1.537	0.360	0.314	0.358	0.332	0.353	23	20	23	21	22	<1.00E+00	>1.00E+02	>1.00E+02	
Melanoma	U251	0.037	3.184	2.701	2.366	2.418	2.050	2.276	85	74	76	64	71	>1.00E+02	>1.00E+02	>1.00E+02	
	LOX IMVI	0.035	1.827	1.721	1.740	1.634	1.636	1.551	94	95	89	89	85	>1.00E+02	>1.00E+02	>1.00E+02	
	M14	0.083	0.504	0.366	0.344	0.393	0.383	0.391	67	62	73	71	73	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-2	0.045	1.350	1.130	1.163	1.105	1.015	0.843	83	86	81	74	61	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-28	0.095	1.718	1.748	1.792	1.711	1.824	2.003	102	105	100	107	118	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-MEL-5	0.070	0.830	0.756	0.716	0.744	0.692	0.664	90	85	89	82	78	>1.00E+02	>1.00E+02	>1.00E+02	
	UACC-257	0.121	1.729	1.649	1.630	1.410	1.396	1.459	95	94	80	79	83	>1.00E+02	>1.00E+02	>1.00E+02	
Ovarian Cancer	UACC-62	0.018	1.901	1.898	1.794	1.820	1.801	1.734	100	94	96	95	91	>1.00E+02	>1.00E+02	>1.00E+02	
	IGROV1	0.086	1.293	0.097	0.073	0.049	0.032	0.037	1	-16	-43	-63	-57	<1.00E+00	1.07E+00	1.50E+01	
	OVCA-3	0.071	1.553	1.364	1.289	1.245	1.060	1.102	87	82	79	67	70	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA-4	0.101	1.436	1.357	1.269	1.246	1.206	1.149	94	87	86	83	78	>1.00E+02	>1.00E+02	>1.00E+02	
	OVCA-5	0.020	1.641	1.540	1.606	1.595	1.634	1.608	94	98	97	100	98	>1.00E+02	>1.00E+02	>1.00E+02	
	SK-OV-3	0.056	0.848	0.834	0.807	0.853	0.821	0.834	98	95	101	97	98	>1.00E+02	>1.00E+02	>1.00E+02	
	Renal Cancer	786-0	0.073	1.816	1.818	1.830	1.853	1.816	1.834	100	101	102	100	101	>1.00E+02	>1.00E+02	>1.00E+02
Prostate Cancer	A498	0.087	1.108	1.080	1.046	1.034	0.988	0.969	97	94	93	88	86	>1.00E+02	>1.00E+02	>1.00E+02	
	ACHN	0.041	2.105	2.060	2.051	1.993	1.958	1.867	98	97	95	93	88	>1.00E+02	>1.00E+02	>1.00E+02	
	CAX1-1	0.033	1.080	1.108	0.941	1.017	1.031	0.959	103	87	94	95	88	>1.00E+02	>1.00E+02	>1.00E+02	
	PCF 193	0.101	0.982	0.589	0.322	0.362	0.450	0.262	55	25	30	40	18	1.23E+00	>1.00E+02	>1.00E+02	
	SN12C	0.054	1.352	1.354	1.353	1.319	1.346	1.257	100	100	97	100	93	>1.00E+02	>1.00E+02	>1.00E+02	
	TR-10	0.057	1.226	1.159	1.058	1.042	0.939	0.802	94	86	84	75	64	>1.00E+02	>1.00E+02	>1.00E+02	
	UO-31	0.095	1.523	1.434	1.395	1.377	1.343	1.340	94	91	90	87	87	>1.00E+02	>1.00E+02	>1.00E+02	
Breast Cancer	DO-31	0.030	0.817	0.520	0.467	0.384	0.426	0.342	62	56	45	50	40	>1.00E+02	>1.00E+02	>1.00E+02	
	FC-3	0.057	1.911	1.810	1.744	1.693	1.359	1.034	95	91	88	70	52	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-231	0.060	3.104	2.284	2.012	1.444	0.809	0.770	73	64	45	25	23	7.57E+00	>1.00E+02	>1.00E+02	
	MDA-MB-231/ATCC	0.045	1.013	1.037	1.036	1.017	1.007	0.974	102	102	100	99	96	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.042	0.873	0.774	0.755	0.805	0.750	0.720	88	86	92	85	82	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-MB-435	0.055	0.491	0.512	0.511	0.508	0.518	0.515	105	105	104	106	106	>1.00E+02	>1.00E+02	>1.00E+02	
	MDA-N	0.041	2.083	2.007	1.738	1.719	1.387	0.96	84	85	82	72	66	>1.00E+02	>1.00E+02	>1.00E+02	
T-47D	BT-549	0.010	0.984	0.809	0.738	0.803	0.677	0.571	82	75	81	68	58	>1.00E+02	>1.00E+02	>1.00E+02	
	T-47D	0.100	1.296	1.457	1.398	1.377	1.432	1.346	113	109	107	111	104	>1.00E+02	>1.00E+02	>1.00E+02	
	T-47D	0.049	0.567	0.582	0.568	0.595	0.566	0.490	103	100	105	100	100	>1.00E+02	>1.00E+02	>1.00E+02	

Fig. 22



Size comparison of Octopus Constructs:






Fig. 24




Fig. 25





Fig. 26



Representative plot of $n = 6$ cytostasis assays; crystal violet

Fig. 27




Fig. 28A




Fig. 28B

OctHER2..... POOct-3HER2——

○● Unbound □■ Cell surface bound ▲△ Intracellular ◇ Catabolized




Fig. 29A




Fig. 29B




Fig. 30A




Fig. 30B

Fig. 31A




Fig. 31B




Fig. 32




Fig. 33




Fig. 34




Figure 35 shows the results of the experiment in which the effect of Rituxan on the binding of OctCD20 to the cell surface and intracellularly was determined. The results are shown as a percentage of total CPM.




Fig. 35